Advances in Biochemistry
Volume 6, Issue 5, October 2018, Pages: 39-46
Received: Oct. 25, 2018;
Accepted: Nov. 9, 2018;
Published: Dec. 14, 2018
Views 695 Downloads 239
Nurit Beyth, Department of Prosthodontics, Hebrew University-Hadassah School of Dental Medicine, Jerusalem, Israel
Edna Blotnick-Rubin, Department of Medical Neurobiology, Institute for Medical Research-Israel–Canada, Hebrew University of Jerusalem, Jerusalem, Israel
Yael Houri-Haddad, Department of Prosthodontics, Hebrew University-Hadassah School of Dental Medicine, Jerusalem, Israel
Shaul Beyth, Orthopedic Surgery Complex, Hadassah University Hospital, Jerusalem, Israel
Andras Muhlrad, Institute of Dental Sciences, Hebrew University-Hadassah School of Dental Medicine, Jerusalem, Israel
Buforin is a cationic antimicrobial peptide (AMP) from the stomach of toads. Buforin II is a derivative of this naturally occurring peptide. Buforin IIB is a synthetic analog of buforin II containing a model α-helical sequence (3xRLLR) at the C-terminus. To further increase the antimicrobial activity and decrease toxicity to eukaryotic cells, new derivatives (buforin III analogs) were designed by substituting amino acids in the buforin IIB sequence. In this work, the antimicrobial activity and the actin- and DNA-binding characteristics of buforin IIIB (RVVRQWPIGRVVRRVVRRVVR) and the newly synthetized buforin IIIE (RLLLRQWPIGRLLRRLLRRLLR) were studied. The antimicrobial activity of buforin IIIB (measured against E. coli and E. faecalis) was significantly greater than that of buforin IIIE, while both peptides were nontoxic to macrophages at the minimal concentrations required to inhibit microbial growth. Actin, which inhibited the antimicrobial activity of the two buforin III analogs, was bundled by both peptides; however, less buforin IIIE than buforin IIIB was needed for bundling. Higher levels of NaCl were needed to unbundle actin bundled by buforin IIIE than actin bundled by buforin IIIB, which indicates that buforin IIIE binds more strongly to actin than buforin IIIB. Actin bundled by either peptide was dissociated with the same concentration of DNA; however, buforin IIIE bound more strongly to DNA than buforin IIIB. These results contribute to the understanding of the antimicrobial mechanism of cationic AMPs in general and histone-derived peptides in particular.
Buforin III Analogs Bind to DNA and Actin and Inhibit Bacterial Growth, Advances in Biochemistry.
Vol. 6, No. 5,
2018, pp. 39-46.
Jenssen H, Hamill P, Hancock R. Peptide antimicrobial agents. Clin Microbial Rev.2006,19: 491-511.
Park CB, Kim MS, Kim SC. A novel antimicrobial peptide from Bufo bufo Gargarizans. Biochem Biophys Res Commun. 1996,218: 408–13.
Kim HS, Yoon H, Minn I, Park CB, Lee WT, Zasloff M, Kim SC. Pepsin-mediated processing of the cytoplasmic histone H2A to strong antimicrobial peptide buforin I. J. Immunol. 2000,165: 3268–74.
Kim HS, Park CB, Kim MS, Kim SC. cDNA cloning and characterization of buforin I, an antimicrobial peptide: a cleavage product of histone H2A, Biochem. Biophys. Res. Commun. 1996,229: 381–7.
Hirsch JG. Bactericidal action of histone. J. Exp. Med. 1958,108: 925-44.
Miller TE, Watson DW, Biochemical characterization of the antimicrobial histone released by deoxyribonuclease and lactic acid. Proc Soc Exp Biol Med. 1969,131: 339-42.
Sol A, Skvirsky Y, Blotnick E, Bachrach G, Muhlrad A. Actin and DNA protect histones from degradation by bacterial proteases but inhibit their antimicrobial activity. Frontiers of Microbiology. 2016, 7: 1248 doi: 10.3389.
Blotnick E, Sol A, Muhlrad A. Histones bundle F-actin filaments and affect actin structure. PLOS ONE. 2017,12: e0183760. https://doi.org/10.1371/journal.pone.0183760.
Park CB, Yi K-S, Matsuzaki K, Kim MS, Kim SC. Structure–activity analysis of buforin II, a histone H2A-derived antimicrobial peptide: The proline hinge is responsible for the cell-penetrating ability of buforin II. Proc Natl Acad Sci U S A. 2000, 97: 8245–50.
Park CB, Kim HS, Kim SC. Mechanism of action of the antimicrobial peptide buforin II: buforin II kills microorganisms by penetrating the cell membrane and inhibiting cellular functions. Biochem Biophys Res Commun. 1998,244: 253–7.
Uyterhoeven ET, Butler CH, Ko D, Elmore DE. Investigating the nucleic acid interactions and antimicrobial mechanism of buforin II. FEBS Lett. 2008,582: 1715–18.
Xie Y, Fleming E, Chen JL, Elmore DE. Effect of proline position on the antimicrobial mechanism of buforin II. Peptides. 2011,32: 677-82.
Jang SA, Kim H, Lee JY, Shin JR, Kim DJ, Cho JH, Kim SC. Mechanism of action and specificity of antimicrobial peptides designed based on buforin IIb. Peptides. 2012,34: 283-9. doi: 10.1016.
Shafer WM Steinberg D, Lehrer RI. in Methods in Molecular Biology 78: Antibacterial Peptide Protocols, ed Shafer W M (Humana Press, Totowa, NJ), 1997, pp 169–186.
Scudiero DA, Shoemaker RH, Paull KD, Monks A, Tierney S, Nofziger TH et al. Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines. Cancer Res. 1988, 48: 4827-33.
Spudich JA, Watt S. The regulation of rabbit skeletal muscle contraction. I. Biochemical studies of the interaction of the tropomyosin-troponin complex with actin and the proteolytic fragments of myosin. J Biol Chem. 1971,246: 4866–71.
Tse WC, Boger DL. A fluorescent intercalator displacement assay for establishing DNA binding selectivity and affinity. Acc. Chem. Res. 2004,37: 61–9.
Muhlrad A, Grintsevich EE, Reisler E. Polycation induced actin bundles. Biophys Chem. 2011, 155: 45-51.
Tang JX, Ito T, Tao T, Traub P, Janmey PA. Opposite effects of electrostatics and steric exclusion on bundle formation by F-actin and other filamentous polyelectrolytes. Biochemistry. 1997, 36: 12600-7.
Vasconcellos CA, Allen PG, Wahl ME, Draven JM, Janmey PA, Stossel TP. Reduction in viscosity of cystic fibrosis sputum in vitro by gelsolin. Science. 1994, 263: 969–7121.
Tang JX, Janmey PA. The polyelectrolyte nature of F-actin and the mechanism of actin bundle formation. J Biol Chem. 1996,271: 8556-63.
Sim S, Wang P, Beyer BN, Cutrona KJ, Radhakrishnan ML, Elmore DE. Investigating the nucleic acid interactions of histone-derived antimicrobial peptides. FEBS Letters. 2017, 591: 706–17.
Zhu WL, Hahm KS, Shin SY. Cell selectivity and mechanism of action of short antimicrobial peptides designed from the cell-penetrating peptide Pep-1. J Pept Sci. 2009,15: 569–75.
Hirakura Y, Kobayashi S, Matsuzaki K. Specific interactions of the antimicrobial peptide cyclic b-sheet tachyplesin I with lipopolysaccharides. Biochim Biophys Acta. 2002,1562: 32–6.
Hao G, Shi Y-H, Ya-Li Tang Y-L, Le G-W. The membrane action mechanism of analogs of the antimicrobial peptide Buforin 2. Peptides. 2009, 30: 1421–7.
Lee HS, Park CB, Kim JM, Jang SA, Park IY, Kim MS, et al. Mechanism of anticancer activity of buforin IIb, a histone H2A-derived peptide. Cancer Lett 2008,271: 47–55.
Bitton RJ, Guthmann MD, Gabri MR, Carnero AJ, Alonso DF, Fainboim L, et al. Cancer vaccines: an update with special focus on ganglioside antigens. Oncol Rep. 2002,9: 267–76
Jang JH, Kim YJ, Kim H, Kim SC, Cho JH. Buforin IIb induces endoplasmic reticulum stress-mediated apoptosis in HeLa cells. Peptides. 2015,69: 144-9.
Brogan TD, Ryley HC, Neale L, Yassa J. Soluble proteins of bronchopulmonary secretions from patients with cystic fibrosis, asthma, and bronchitis. Thorax. 1975, 30:72–79. PMID: 47656 36.
Jay X. Tang JX, Wen Q, Bennett A, Kim B, Sheils CA et al. Anionic poly(amino acid)s dissolve F-actin and DNA bundles, enhance DNase activity, and reduce the viscosity of cystic fibrosis sputum. Am J Physiol—Lung Cellular and Molecular Physiol. 2005, 289: L599–L605.
Bucki R, Byfield FJ, Janmey PA. Release of the antimicrobial peptide LL-37 from DNA/F-actin bundles in cystic fibrosis sputum. Eur Respir J. 2007, 29: 624–32.
Pavia KE, Spinella SA and Elmore DE. Novel histone-derived antimicrobial peptides use different antimicrobial mechanisms. Biochim Biophys Acta. 2012,1818: 869–76.
Cutrona KJ, Kaufman BA, Figueroa DM, Elmore DE. Role of arginine and lysine in the antimicrobial mechanism of histone derived antimicrobial peptides. FEBS Lett. 2015,589: 3915-20.